The executive of a private health group has expressed disappointment that a planned inquiry into South Africa’s private healthcare market by the Competition Commission will not also umbrella the pharmaceutical sector. Netcare CEO Richard Friedland offered the remarks on Monday, noting that consumers pay “40 percent more” for drugs in South Africa. The Commission’s planned review of the healthcare market will bring private hospitals and medical schemes under a close watch but appears to let the pharmaceutical sector off the hook under the argument that pharmaceutical prices are already regulated. Further, Friedland said the allowance of parallel imports of drugs could help lower costs for consumers. Netcare is currently the nation’s third-largest private hospital group.
Featured News
Trump’s Defamation Case Against New York Times Advances in Federal Court
Nov 19, 2026 by
CPI
Musk’s xAI Faces Skeptical US Judges Over California AI Disclosure Law
Nov 19, 2026 by
CPI
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff